image credit: Unsplash

5 FDA approval decisions to watch in the 2nd quarter

March 30, 2020


With the coronavirus pandemic disrupting nearly every part of the drugmaking industry, there’s concern the ripple effect will spread to the Food and Drug Administration, too.

While the agency is focused on responding to the outbreak, it still needs to carry out the critical work of reviewing experimental medicines for other diseases.

The first quarter passed with little apparent disruption, evidenced by last week’s on-time approval of Bristol Myers Squibb’s multiple sclerosis drug Zeposia. But the FDA will be under immense pressure over these next few months to prove that, amid a crisis, it can maintain business as usual.

Read More on Biopharma Dive